Skip to Content

Brincidofovir FDA Approval Status

FDA Approved: No
Generic name: brincidofovir
Company: Chimerix, Inc.
Treatment for: Smallpox

Brincidofovir is a nucleotide analog broad-spectrum antiviral in development as a medical countermeasure for smallpox.

Development Timeline for brincidofovir

DateArticle
Apr 28, 2020Chimerix Receives FDA Clearance for Rolling Submission of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox
Nov 13, 2014Chimerix's Brincidofovir Selected for Use in Ebola Clinical Trial in West Africa
Oct  6, 2014Chimerix Announces Emergency Investigational NDA for Brincidofovir Authorized by FDA for Patients With Ebola Virus Disease

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.